Total: $606.75M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Advanced Tissue Sciences Inc. (ATIS)

Private placement of common stock

3.53S

$14.7

Advanced Tissue Sciences raised $14.7M in a private placement

Alliance Pharmaceutical Corp. (ALLP)

Private placement of common stock

4.3S and W for 4.3S

$15

Alliance raised $15M with the placement of 4.3M shares and warrants to receive 4.3M shares with a group of institutional and individual investors (11/1)

Ariad Pharmaceuticals Inc. (ARIA)

Private placement of common stock

1.9S

$8

Ariad raised about $8M with the placement of about 1.9M shares to selected institutional investors (11/1)

Cel-Sci Corp. (AMEX:CVM)

Equity and debt financings

N/A

$2.2

Cel-Sci raised more than $2.2M; all officers of the company participated in the equity financings (11/28)

Genetronics Biomedical Corp. (AMEX:GEB)

Private placement of special warrants

5.2W

$2.3

Genetronics sold 5.2M special warrants at 45 cents each; each warrant entitles the holder to acquire one common share of Genetronics and one-half of a non-transferable warrant on the exercise or deemed exercise of the special warrant (11/15)

Genta Inc. (GNTA)

Private placement of common stock

2.5S

$32.7

Genta raised $32.7M with the sale of 2.5M shares to Franklin Templeton and SF Capital Partners (11/28)

Hercules Development Group (now called Astralis Pharmaceuticals Ltd.; OTC BB:ASTR)

Equity financing

N/A

$3.2

The financing of $3.2M was made simultaneously with the closing of a merger agreement between Hercules and Astralis LLC (11/14)

MGI Pharma Inc. (MOGN)

Private placement of common stock

0.9S

$11.8

MGI Pharma entered an agreement to sell the final 900,000 shares of its shelf registration, raising $11.8M, to U.S. Bancorp Piper Jaffray, which purchased the first 4M of the registration in May (11/27)

Neoprobe Corp. (OTC BB: NEOP)

Equity financing agreement

N/A

¿

Neoprobe entered an agreement with Fusion Capital Fund II LLC for Fusion to buy up to $10M of NeoProbe's common stock over 40 months (11/29)

NeoTherapeutics Inc. (NEOT)

Private placement of common stock

0.95S

$3.8

NeoTherapeutics raised $3.8M in a private placement; Cantor Fitzgerald & Co. served as placement agent (11/13)

Ophidian Pharmaceuticals Inc. (OTC BB:OPHD)

Private placement of convertible debentures

N/A

$2

Ophidian raised $2M in an offering of debentures convertible into shares of Ophidian common stock at 50 cents a share (11/21)

Palatin Technologies Inc. (AMEX:PTN)

Private placement of common stock

4.9S

$11

Palatin raised $11M through the private placement of 4.9M shares; investors include Credit Suisse Equity Fund Global Biotech, Bernische Lehrerversicherungskasse, Cantrade Invest Biotech Fund, Anglo Irish Bank, Sectoral Asset Management Fund, OrbiMed Advisors LLC, Perceptive Life Sciences Fund and the Clearwater Fund (11/12)

Peregrine Pharmaceuticals Inc. (PPHM)

Private placement of common stock and warrants

5.75S and W for 1.725S

$5.75

Peregrine raised $5.75M in an offering of 5.75M shares and warrants to purchase 1.725M shares; Zimmer Lucas Partners LLP led the offering; the company also issued 200,000 shares to Atlas Capital Services LLC, which acted as placement agent (11/19)

Ribozyme Pharmaceuticals Inc. (RZYM)

Private placement of common stock and warrants

2.3S and W for 0.23S

$9.5

Ribozyme raised $9.5M through the sale of about 2.3M shares and five-year warrants to purchase 226,191 shares; ABN AMRO Inc. served as financial adviser and placement agent of the offering (11/29)

Sepracor Inc. (SEPR)

Private placement of convertible subordinated notes

N/A

$400

Sepracor raised $400M in a private placement with qualified institutional buyers (11/8)

The Immune Response Corp. (IMNR)

Private placement of a convertible note and warrant

W for 1.73S

$2

Immune Response raised $2M in a placement with Kevin Kimberlin Partners LP (11/13)

ViroPharma Inc. (VPHM)

Private placement of common stock

4S

$82.8

ViroPharma placed 4M shares at $20.70 each with Morgan Stanley, raising $82.8M (11/15)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; OTC BB = Over the Counter Bulletin Board

No Comments